Recent studies indicate that losing weight may not be enough to prevent future gain, with emerging evidence suggesting fat cells possess a ‘memory’ of past obesity. Research conducted on mice and published in Cell Reports details how this biological mechanism works.
How Fat Cells 'Remember'
Researchers at Case Western Reserve University discovered that the hormone asprosin, produced by fat tissue, remains elevated even after weight loss. This is due to lasting changes within the cells’ DNA structure – specifically in the Fbn1 gene – which keeps asprosin production active. The process resembles a “light switch” remaining on even when not triggered, according to study author Seth Field.
The Role of Asprosin and TGF-beta-1
The research team found that exposure to transforming growth factor-beta-1 (TGF-beta-1), an inflammatory molecule associated with obesity, increased asprosin production in fat cells. This effect persisted for at least 14 days after the initial exposure ended, altering chromatin packaging and locking the Fbn1 gene into an active state.
Implications for Weight Loss Treatments
Mice that had previously been obese continued to exhibit high asprosin levels even after achieving a healthy weight. When reintroduced to a high-fat diet, these mice regained more weight than control groups. Blocking asprosin or its related pathway partially prevented this regain. A study in 2025 found eighty-three percent of patients regaining at least 25% of lost weight within one year of stopping tirzepatide treatment.
Potential for Intergenerational Effects
The research also suggests a potential link between maternal obesity and offspring predisposition to weight gain. Offspring of obese mice, as well as those exposed to TGF-beta-1 during pregnancy, showed elevated asprosin levels and increased weight gain on a high-fat diet. This indicates that metabolic health during pregnancy may influence fetal fat cell development.
Current Weight Loss Drug Landscape
While medications like Ozempic have gained popularity – with eleven percent of U.S. adults using GLP-1s for weight loss in 2024, up from three percent – many users experience weight regain after stopping treatment. A program launched by the Trump administration provided discounted access to these drugs for seniors beginning in July 2026.
💬 Comments (0)